One shelf, two receptors. 4 of these 5 are GHRH analogs and 1 is a ghrelin mimetic, which decides what else they touch on the way to growth hormone — and no price list has to print it.
Four of these five are recorded as the same kind of molecule
Sermorelin, Tesamorelin, CJC-1295 (no DAC) and CJC-1295 + DAC all carry the same recorded mechanism, and each of those 4 cells is traced to a document. What the phrase means is at its plainest in the oldest of them, which describes sermorelin by giving its sequence rather than its category.
Synthetically produced GRF1-29 (Sermorelin) has an amino acid composition identical to the N-terminal 29 amino acids sequence of the natural hypothalamic GHRH1-44
Esposito et al. 2003, abstract, read September 2026
An analog of the hormone, then — the first twenty-nine amino acids of a forty-four-amino-acid hypothalamic peptide, arriving at the receptor the body’s own GHRH arrives at. The other three in this group are recorded under the same class for the same reason. What separates them is not the door they knock on; it is how long they last once they are through it, which is the next section but one.
There are two classes in this column and no third, which is what makes it a line rather than a spectrum. A class is also not a license, a safety finding or a dose: it is one row of the matrix, and the other 4 disagree with it constantly.
The one that is not, and the receptor its own paper pinned it to
Ipamorelin is the exception, and the paper that introduced it did not leave the question open. Its authors ran the compound against antagonists of both receptor systems and reported which one answered.
A pharmacological profiling using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor.
Raun et al. 1998, abstract, read September 2026
The later paper this site cites for the cell says the same thing in the vocabulary the cell uses, describing ipamorelin as “ipamorelin, a selective growth hormone secretagogue and agonist of the ghrelin receptor”. Ghrelin is a stomach hormone; the receptor it acts on is not the GHRH receptor, and a molecule that reaches growth hormone through it is doing a different thing on the way, whatever the shelf it is sold from says.
That is the whole of the difference this page is about, and it is also the reason the two are so often sold together rather than instead of each other. What the literature records about combining them is on sermorelin vs ipamorelin, which takes one such pair in detail; what the sellers do with it is below.
Every listing here that names two of them crosses that line
Here is what makes the split worth a page rather than a footnote. 5 of the 19 priced listings this site has read name more than one of these 5 molecules, across 3 of the 14 sellers on the roster — and 5 of those 5 put one molecule from each side of the split into the same product. Not one of them pairs two molecules from the same class.
None of that is in the titles. What these records hold for a listing is its name, its figure and the molecules the figure buys — there is no mechanism field on a seller record here, and nothing in them says a seller ever mentions one. But the pattern in what they buy is exact, and it is the pattern the literature would predict from two different receptors rather than one.
Listings that name more than one of these 5 molecules, and what they pair with what.
Listings naming more than one of the 5
5 of 19
From 3 of the 14 sellers on this roster.
Of those, pairing across the two classes
5 of 5
The empty part of this bar is the number that stay inside one class, and it is zero.
Of those, stating what dose the money buys
0 of 5
None of them. The pairing is named; the amount of either molecule in it is not.
Of those, saying which CJC-1295 form is inside
3 of 5
2 name a CJC-1295 product without saying which of this site's two records it is.
Counted from the 19 priced listings behind the board, each read off the seller’s own page and dated. The per-seller working is on the seller records.
What the class does not settle
The class is a weak predictor of the thing a buyer plans around. Inside the group of 4, the measured half-lives run from 8 min for Tesamorelin to 5.8–8.1 days for CJC-1295 + DAC — a factor of somewhere between 1044 and 1458, between two molecules the mechanism row files together. One is injected daily and the other weekly, and the row that groups them says nothing about either schedule.
A fourth member of the class cannot be put on that scale at all. CJC-1295 (no DAC) is recorded as not reported in humans, which is what the review covering that exact compound reports. Same class, same backbone, and no answer to how long it lasts.
The other rows disagree with the class too. The regulatory record splits this same group of 4 into 3 on its own, and which of these is FDA approved? takes that column the way this page takes the mechanism one. Nothing on this page says a molecule in either class is safer, stronger or better suited to anybody — that is a clinician’s judgment about a person, and this is a row in a table.
How the 4 in the larger class differ from one another
Sermorelin — half-life recorded as 10–20 min; regulatory status recorded as withdrawn.
Tesamorelin — half-life recorded as 8 min; regulatory status recorded as approved (Egrifta SV).
CJC-1295 (no DAC) — half-life recorded as not reported in humans; regulatory status recorded as not approved.
CJC-1295 + DAC — half-life recorded as 5.8–8.1 days; regulatory status recorded as not approved.
Each figure is the one printed in the matrix, with the label or trial behind it on the sources page.
Plasma half-life, logarithmic scale, ordered shortest first. The spacing is the point: linear spacing would put 3 of the 4 bands drawn here inside one smudge at the left edge. Where a figure is a range the mark is the range; where a single value is recorded the mark is a tick, because a bar there would draw a span nobody measured. CJC-1295 (no DAC) has no band here: no human study reports a figure to draw.
Sources
Every pharmacological figure on this page comes from one of the documents below. The quotations above are printed from the abstracts those documents publish, not from summaries of them, and each is attributed to the document the cell it belongs to actually cites.
9 documents, in the order the figures above use them. The date on each is the one printed on the document.
1Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM.PEGylation of growth hormone-releasing hormone (GRF) analogues. Advanced Drug Delivery Reviews, volume 55, issue 10, pages 1279–1291.Document date: 2003-09-26. PMID 14499707, doi:10.1016/s0169-409x(03)00109-1. Read September 2026.
4Theratechnologies Inc., prescribing information approved by the Food and Drug Administration.EGRIFTA SV (tesamorelin) for injection, for subcutaneous use — full prescribing information. DailyMed structured product label, National Library of Medicine.Document date: label face date: Revised 03/2024; label version published 2026-07-31. SPL set id 3d783378-b02d-4f19-99dd-0fc91a042224, Initial U.S. Approval 2010. Read September 2026.
5Theratechnologies Inc., prescribing information approved by the Food and Drug Administration.EGRIFTA WR (tesamorelin) for injection, for subcutaneous use — full prescribing information. DailyMed structured product label, National Library of Medicine.Document date: label face date: Revised 03/2025; label version published 2026-08-03. SPL set id 839334d3-8c1d-4c26-9036-2ab524a6ea75, Initial U.S. Approval 2010. Read September 2026.
The board below is every listing in these records that buys Ipamorelin. It is the same set as the pairings above, because no figure here buys that molecule on its own. Each figure carries the qualifier that makes it mean something: what kind of number it is, what period it is charged for, what dose it buys, and the day it was read. Nothing here names a cheapest. The full roster of 19 listings across 14 sellers is on the home page.
5 priced listings from 3 of the 3 sellers below, quoted against 1 different billing cycle, in the order the records are written — not ranked, not sorted by size, and no cheapest is named, because a floor, a standing rate, a prepaid total and an introductory price are four different measurements. Every figure read off the seller's own page, September 2026.
The board scrolls sideways; the seller column and the button column both stay put.
Read off each seller’s own page and dated in the row. Nothing here is scored or ranked, and the rows are in the order the sellers were read.
The list that follows is drawn from all 5 molecules rather than from the board above, so it is wider by 1 record: a seller carrying more than one of these molecules whose figures this site declines to publish, with the reason on its own record.
4 of this site’s 14 seller records carry more than one of Sermorelin, Tesamorelin, Ipamorelin, CJC-1295 (no DAC), CJC-1295 + DAC — which is the only reason they are listed here rather than everyone we have read. Their figures, with every qualifier attached, are in the board above. Some sellers here pay us a commission; it does not change who is listed or what their figure says — how we earn.
ElitePhysiqMD
Prices four listings across three of these molecules on one catalog page and states a dose on none of them. Tesamorelin alone and tesamorelin with ipamorelin carry the identical figure, which is the clearest thing on the page: adding a second molecule changes the price by nothing. The catalog also prints “Save 10% with subscription” beside the figures.
Every figure on this catalog is a floor — the page prints “from” in front of all of them — and none states a dose, so the gaps between the four are gaps between starting points, not between what anyone pays. The CJC-1295 listing is sold only as a pairing and never says which form of CJC-1295 it contains.
The strongest single illustration on this site of the problem it exists to describe: sermorelin and tesamorelin are offered side by side in one medication picker, at the same struck-through figure and the same discounted figure, over the same supply. Two molecules whose recorded half-lives differ by roughly an order of magnitude, priced as though the choice between them were a flavor.
Sells a tier, not a drug. The figure buys sermorelin and ipamorelin together with the other items listed against it, so it is not a price for either peptide and is not used as one here. Neither molecule is offered on its own anywhere on the page.